Abstract
Development of drug resistance in HIV infected children with treatment failure is a major impediment to selection of appropriate therapy. HIV genotype resistance assays predict drug resistance on the basis of mutations in the viral genome. However, their clinical utility, especially in a resource limited setting is still a subject of debate. The authors report two cases in which both the children suffered from treatment failure of various antiretroviral therapy regimes. In both the cases, Genotype Resistance Testing (GRT) prompted a radical change from proposed failure therapy as per existing guidelines. GRT was specifically important for the selection of a new dual Nucleoside reverse transcriptase inhibitors (NRTI) component of failure regimen by identifying TAMS and M184V mutations in the HIV genome. These case reports highlight the importance of GRT in children failing multiple antiretroviral regimes; and emphasizes the need to recognize situations where GRT is absolutely essential to guide appropriate therapy, even in a resource limited setting.
References
Deshpande A, Karki S, Recordon-Pinson P, Fleury HJ. Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses. 2011;27:1345–7.
Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23:1303–8.
Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther. 2009;14:1005–9.
Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected withhuman immunodeficiency virus type 1. Women and infants transmission study group. N Engl J Med. 1997;336:1337–42.
Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–18.
Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369–79.
Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The viradapt study: week 48 follow-up. Antivir Ther. 2000;5:65–70.
Kumarasamy N, Madhavan V, Venkatesh K, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009;49:306–9.
Conflict of Interest
None.
Role of Funding Source
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, I., Parikh, S. HIV Genotype Resistance Testing in Antiretroviral (ART) Exposed Indian Children—A Need of the Hour. Indian J Pediatr 80, 340–342 (2013). https://doi.org/10.1007/s12098-012-0752-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-012-0752-6